Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2303-2309

  Hubner, Richard A ^a   Muir, Kenneth R ^b   Liu, Jo Fen ^b   Logan, Richard F A ^b   Grainge, Matthew J ^b   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FOLIC ACID; ORNITHINE DECARBOXYLASE; PLACEBO;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; MALE; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

ADENOMA; ADULT; AGED; ANTICARCINOGENIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; FEMALE; GENES, APC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORNITHINE DECARBOXYLASE; PROGNOSIS;

EID: 42249097559     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4599     Document Type: Article

References (35)

1. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000;51:511-23.
2. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
3. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
4. Flossmann E, Rothwell PM. Effect of aspirin on longterm risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13.
5. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002;122:78-84.
6. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003;348:879-80.
7. Babbar N, Ignatenko NA, Casero RA, Jr., Gerner EW. Cyclooxygenase- independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 2003;278:47762-75.
8. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
9. Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A, Suzuki F. Tumor angiogenesis and polyamines: α-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res 1990;50:4131-8.
10. Meyskens FL, Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51.
11. Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase: structure, function and translational regulation. Biochem Soc Trans 1994;22:846- 52.
12. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 1993;90:7804-8.
13. Guo Y, Harris RB, Rosson D, Boorman D, O'Brien TG. Functional analysis of human ornithine decarboxylase alleles. Cancer Res 2000;60:6314-7.
14. Martinez ME, O'Brien TG, Fultz KE, et al.Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 2003;100:7859-64.
15. Barry EL, Baron JA, Bhat S, et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst 2006;98:1494-500.
16. Logan RFA, Muir KR, Grainge MJ, Shepherd VC, on behalf of the UKCAP Trial Group. Aspirin for the prevention of recurrent colorectal adenomas - results of the UKCAP trial. Gut 2006;55:A90.
17. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-62.
18. Kleinbaum DG, Krupper LL, Morgenstern H. Epidemiologic research. New York: Von Nostrand Reinhold Co.; 1982.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
20. Ury HK, Fleiss JL. On approximate sample sizes for comparing two independent proportions with the use of Yates' correction. Biometrics 1980;36:347-51.
21. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002;3:166-74.
22. Hanif R, Pittas A, FengY, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
23. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
24. Hughes A, Smith NI, Wallace HM. Polyamines reverse non-steroidal anti-inflammatory drug-induced toxicity in human colorectal cancer cells. Biochem J 2003;374:481-8.
25. Ignatenko NA, Babbar N, Mehta D, Casero RA, Jr., Gerner EW. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog 2004;39:91-102.
26. Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of β-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 2000;21:1935-40.
27. Fultz KE, Gerner EW. APC-dependent regulation of ornithine decarboxylase in human colon tumor cells. Mol Carcinog 2002;34:10-8.
28. Giardiello FM, Hamilton SR, Hylind LM,Yang VW, Tamez P, Casero RA, Jr. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 1997;57:199-201.
29. Olson JW, Crooks PA. Effect of nicotine and N′-nitrosonornicotine on rat lung and trachea ornithine decarboxylase activity. Carcinogenesis 1985;6:1517-9.
30. Visvanathan K, Helzlsouer KJ, Boorman DW, et al. Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol 2004;171:652-5.
31. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol1 993;35:219-26.
32. He J, Whelton PK,Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998;280:1930-5.
33. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
34. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
35. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.